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Purpose: Osteomyelitis is a progressive infectious process resulting in inflammatory 
destruction and necrosis of bone. The long-term administration of high-dosage antibiotics is 
required to treat osteomyelitis, owing to the limited distribution of antibiotics within bone. 
Therefore, targeted delivery of antibiotics to bone promises to improve therapeutic effectiveness. 
Methods: We synthesized quinolones such as levofloxacin and norfloxacin conjugated to an 
acidic oligopeptide, which works as a bone-targeting carrier after systemic administration. The 
therapeutic effectiveness of the conjugated quinolones in osteomyelitis was evaluated using a 
mouse model of osteomyelitis, created by inoculating Staphylococcus aureus into the tibia of 
mice. Results: With intravenous injection, the conjugated quinolones selectively distributed to 
bone, reaching concentrations up to 100-fold those of non-conjugated quinolones. Single 
intravenous injection of levofloxacin as well as conjugated levofloxacin exhibited antibiotic 
effects in the osteomyelitis mouse model; conversely, neither conjugated nor non-conjugated 
norfloxacin was effective. The antibiotic effect of conjugated levofloxacin persisted to at least 6 
days after injection, whereas the effect of non-conjugated levofloxacin was temporary. 
Conclusion: The selective bone delivery of quinolones conjugated with an acidic oligopeptide 
may be effective in treating osteomyelitis, although the resulting concentration of antibiotic may 
be insufficient to completely kill S. aureus. 
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Introduction 
Osteomyelitis is an inflammation of bone marrow and surrounding cortical bone that 
results in bone destruction and necrosis. Historically, osteomyelitis has been categorized as acute, 
subacute, or chronic based on the time of disease onset. Acute osteomyelitis develops within 2 
weeks after disease onset; subacute osteomyelitis, within one to several months; and chronic 
osteomyelitis, after a few months. Staphylococcus aureus is commonly implicated in most cases 
of acute and chronic osteomyelitis and is responsible for up to 90% of acute hematogenous 
osteomyelitis in children. In adults, osteomyelitis most often results from the contiguous spread 
of microbes, usually involving multiple organisms (1-4). Acute hematogenous osteomyelitis is 
managed by careful evaluation of microbial etiology and susceptibility, and a 4- to 6-week course 
of appropriate antibiotic therapy (5). Chronic osteomyelitis is generally treated with surgical 
debridement and the administration of parental antibiotics such as β-lactams or aminoglycosides. 
Without adequate debridement, most antibiotic regimens fail, even with prolonged therapy. After 
the removal of necrotic tissue, the remaining bed of tissues must be considered to be 
contaminated with the responsible pathogens. Antibiotic treatment for at least 4 weeks is 
recommended (3, 6, 7). Moreover, the serum bactericidal titer, which is defined as the maximal 
dilution of serum able to kill the infecting organism in vitro, should be at least 1:2 for acute 
osteomyelitis treatment and at least 1:4 for chronic osteomyelitis treatment (8). The long-term 
administration of high-dosage antibiotics is required to treat osteomyelitis, owing to a lack of 
antibiotic penetration into bone tissue. 
Various studies have suggested that the local application of antibiotics using 
antibiotic-impregnated bioimplants such as polymethylmethacrylate beads, hydroxyapatite bone 
cement, or biodegradable microspheres provide higher local antibiotic concentrations than those 
achievable with intravenous administration, with the additional advantage of avoiding toxicity 
associated with high levels of drug in the plasma (9-14). However, the bioimplant methodology 
appears to be useful only in chronic osteomyelitis, because surgical debridement is not necessary 
in acute osteomyelitis. Furthermore, the invasive procedure required for placing bioimplants may 
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result in secondary bone infections. Therefore, the development of non-invasive approaches, 
including oral antibiotics that target the bone, can enhance the clinical accessibility and 
convenience of antibiotic therapy for osteomyelitis patients. 
Recently, a novel drug delivery system using acidic oligopeptides to target the bone was 
proposed. This unique approach is based on the physical properties of several non-collagenous 
bone proteins that have repetitive sequences of acidic amino acids (L-Asp or L-Glu) and bind to 
hydroxyapatite (15-17). Osteopontin and bone sialoprotein, two major non-collagenous proteins 
in bone, have L-Asp and L-Glu repetitive sequences, respectively, and rapidly bind to 
hydroxyapatite after secretion in osteoblastic cell culture (18-20). To determine the binding 
affinity of acidic oligopeptides to hydroxyapatite, homopeptides consisting of two to ten residues 
of acidic amino acids were conjugated with 9-fluorenylmethylchloroformate and the binding 
affinities were investigated in vitro. The results indicated that the dissociation constants of the 
acidic oligopeptides decreased with increasing numbers of acidic amino acid residues, and the 
maximal binding rates reached a plateau at six residues, which were independent of acidic amino 
acid specie (Asp or Glu) and optical isomeric form (L or D) (21). In vivo, fluorescein-labeled 
L-Asp hexapeptide accumulated specifically in bone at 24 h after systemic administration in 
mice and was not detected in other tissues. Surprisingly, fluorescein-labeled L-Asp hexapeptide 
was detectable in bone 14 days after administration (22). 
Quinolones such as levofloxacin (LVFX) and norfloxacin (NFLX) have a broad spectrum 
of activity in vitro, including activity against the Gram negative organisms, S. aureus and S. 
epidermidis; therefore, increasing the quinolone concentration in bone should increase 
therapeutic effectiveness in patients with osteomyelitis (23-25). In the present study, we 
conjugated L-Asp hexapeptides to LVFX and NFLX, and evaluated their bone-targeting 
properties and therapeutic effectiveness in a mouse model of osteomyelitis. 
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Materials and Methods 
Synthesis of L-Asp hexapeptide-conjugated levofloxacin 
LVFX was esterified with glycolic acid before conjugation to L-Asp hexapeptide. Oxalyl 
chloride (2.76 mmol) was added to a cooled solution of LVFX (1.38 mmol) in dichloromethane 
(15 ml) including dimethylformamide (DMF; 0.1 ml), and the reaction mixture was stirred for 
2 h at room temperature. Dichloromethane and unreacted oxalyl chloride were evaporated, and 
the samples were left until completely dry. The residue was dissolved in dichloromethane (10 ml), 
then dimethylaminopyridine (4.15 mmol) and benzyl glycolate (1.66 mmol) were added, and the 
solution was stirred overnight at 4°C. The resulting benzyl glycolyl ester of LVFX was purified 
by reverse-phase high performance liquid chromatography (RP-HPLC) with a YMC D-ODS-5 
120A column (20 × 250 mm, YMC Co. Ltd., Kyoto, Japan) in 0.1% trifluoroacetic acid 
(TFA)-acetonitrile solvent at a flow rate of 8 ml/min and with monitoring at 210 nm. For the 
removal of benzyl by catalytic reduction, the benzyl glycolyl ester of LVFX was dissolved in 
methanol (10 ml) containing 0.5 ml of 50% acetic acid, and then a palladium suspension was 
added. The reaction mixture was stirred in a stream of hydrogen for 5 h at room temperature, 
followed by purification with RP-HPLC as described above. The resulting glycolyl ester of 
LVFX (LVFX-ga) was used in the conjugation reaction with L-Asp hexapeptide.  
Starting with hydroxymethylphenoxymethyl resin (HMP resin or Wang resin) anchored 
with Nα-(9-fluorenylmethyloxycarbonyl)-L-aspartic acid β-tert-butyl ester 
[Fmoc-L-Asp(OBut)-OH], the Fmoc-[L-Asp(OBut)]6-O-HMP-resin (0.30 mmol) was 
constructed using an Fmoc solid-phase method and a peptide synthesizer (ABI 433A; Applied 
Biosystems, CA, USA) and employing 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) as a coupling reagent. The peptide resin was treated with 20% 
piperidine in N-methylpyrolidone and was coupled with LVFX-ga (0.30 mmol) by 
N,N′-dicyclohexylcarbodiimide (DCC; 0.39 mmol) in a mixture of DMF (3 ml) and 
dichloromethane (15 ml) for 6 h. The resulting LVFX-ga-[Asp(OBut)]6-O-HMP-resin was 
washed with DMF and dichloromethane-methanol (1:1) and was dried in vacuo prior to cleavage 
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and deprotection with 95% TFA (10 ml) at room temperature for 1.5 h. The resin was removed 
by filtration, and the filtrate was evaporated and lyophilized. The crude product was purified by 
RP-HPLC and lyophilized as described above. The synthesized LVFX-D6 was subjected to fast 
atom bombardment-mass spectroscopy (FAB-MS) analysis (JMS-DX300 mass spectrometer, 
JEOL, Ltd., Tokyo, Japan). 
 
Synthesis of L-Asp hexapeptide-conjugated norfloxacin 
NFLX was amidated with glycolic acid, followed by esterification with succinic acid. To 
a mixture of NFLX (1.57 mmol), glycolic acid (1.57 mmol), and N-methylmorpholine (3.13 
mmol) in DMF (25 ml) was added o-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (1.57 mmol). The reaction mixture was stirred overnight at 4°C and then 
evaporated until dry. The residue was washed with 50% methanol, 5% acetic acid, and dH2O. 
The resulting glycolyl-NFLX (NFLX-ga) was dried in vacuo. Succinic anhydride (3.18 mmol) 
was added to the mixture of NFLX-ga (1.06 mmol) and dimethylaminopyridine (3.18 mmol) in 
DMF (30 ml). The reaction mixture was stirred for 48 h at 4°C and then evaporated until dry. 
The residue was washed with 3% acetic acid and then with dH2O, followed by drying in vacuo. 
The resulting NFLX-ga hemisuccinate (NFLX-ga-suc) was used for further conjugation with 
L-Asp hexapeptide. 
NFLX-ga-suc (0.30 mmol) and H-[Asp(OBut)]6-O-HMP-resin (0.30 mmol) were reacted 
in the presence of DCC (0.39 mmol) in the same manner as described above for the synthesis of 
L-Asp hexapeptide-conjugated LVFX. The product was obtained by treating the resin with 95% 
TFA, followed by purification with RP-HPLC and lyophilization. Synthesized NFLX-D6 was 
subjected to FAB-MS analysis. 
 
HPLC analysis  
The concentrations of LVFX, LVFX-D6, NFLX, NFLX-ga, and NFLX-D6 were 
determined using an HPLC system (Shimadzu, Kyoto, Japan) equipped with a Shim-pack 
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CLC-ODS column (6 × 150 mm, Shimadzu). The mobile phase for LVFX, LVFX-D6, NFLX, 
and NFLX-ga was 15% acetonitrile in 0.1% TFA, and that for NFLX-D6 was 23% acetonitrile in 
0.1% TFA. The flow rate was 1 ml/min. For fluorescence detection, the excitation and emission 
wavelengths were 296 nm and 500 nm, respectively, for LVFX and LVFX-D6 and were 281 nm 
and 440 nm, respectively, for NFLX, NFLX-ga, and NFLX-D6. The compounds were quantified 




Hydroxyapatite beads (Bio-Rad Laboratories, CA, USA) were suspended in 50 mM 
Tris-HCl-buffered saline, pH 7.4, at a concentration of 100 μg/200 μl. LVFX, LVFX-D6, NFLX, 
NFLX-ga, and NFLX-D6 were respectively mixed with the hydroxyapatite suspension at final 
concentrations of 0.1, 0.3, 1.0, 3.0, 10.0, and 30 μM in a 400-μl final volume. The mixtures were 
agitated at 37°C for 1 h, followed by centrifugation at 12,000 × g for 5 min to capture the 
quinolone-bound hydroxyapatite beads. The supernatants were analyzed by HPLC to determine 
the amount of unbound quinolone. The amount of quinolone bound to the hydroxyapatite beads 
was calculated by subtracting the amount of unbound quinolone from the total amount of 
quinolone added to each tube. 
 
Pharmacokinetic experiments and tissue distribution 
All animal experiments were conducted according to the guidelines of the Institutional 
Animal Care and Use Committee of Kanazawa University. Experiments were performed using 
female ddY mice (8 to 10 weeks old). For the pharmacokinetic study, a dosage of 27.7 μmol/kg 
of LVFX or LVFX-D6 (equivalent to 10 mg/kg LVFX), or a dosage of 31.3 μmol/kg of NFLX or 
NFLX-D6 (equivalent to 10 mg/kg NFLX) was injected into the jugular vein of mice. Using 
heparinized capillary tubes, blood samples were collected from the intraorbital venous plexus of 
the mice under diethyl ether anesthesia at fixed time intervals. The plasma was separated by 
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centrifugation and stored at -80°C until assayed. Acetonitrile was added to each plasma sample, 
and the samples were mixed by vortexing and then centrifuged at 12,000 × g for 10 min. Sample 
supernatants were analyzed by HPLC. For determining tissue distribution, mice were sacrificed 
by decapitation at 2 h after a single injection, and multiple tissues, including tibia, bone marrow, 
brain, heart, lung, liver, spleen, intestine, kidney, and muscle, were dissected. The tibiae were 
demineralized by incubation in 200 μl of concentrated HCl at 60°C for 2 h; then 400 μl of 10 M 
NaOH were added, and the samples were mixed at room temperature for 3 h. The solutions were 
neutralized by adding 200 μl of concentrated HCl and 1 ml of 1 M phosphate buffer (pH 7.0). 
The other tissues were homogenized in saline, and 200 μl of each homogenate were mixed with 
200 μl of 5 M NaOH at room temperature for 3 h. The solutions were neutralized by adding 
200 μl of 5 M HCl and 1 ml of 1 M phosphate buffer. This method resulted in the hydrolysis of 
more than 95% of LVFX-D6 and NFLX-D6 to LVFX and NFLX, respectively. To determine the 
extent of biological hydrolysis of LVFX-D6 and NFLX-D6 to LVFX and NFLX-ga, respectively, 
in the tissues, 1 ml of 1 M phosphate buffer was added to each tissue homogenate without the 
addition of NaOH and HCl. The digested tissues were extracted twice with chloroform to recover 
LVFX, NFLX, and NFLX-ga, and the combined chloroform extracts were evaporated. The 
residues were reconstituted with a HPLC mobile phase; each sample was filtered through a 
Millex-HV 0.45-μm filter (Millipore, MA, USA), and the flow-through was analyzed by HPLC. 
 
Antibiotic effectiveness in a mouse model of osteomyelitis 
Female ddY mice (8 to 10 weeks old) were inoculated with S. aureus (JCM 2413, RIKEN, 
Saitama, Japan) to create experimental osteomyelitis. Briefly, the right tibia was exposed under 
diethyl ether anesthesia, and a small hole was drilled in the proximal third portion of the tibia 
with a 26-gauge needle. One microliter of an S. aureus suspension containing 105 
colony-forming units (cfu) was injected into the cavity, and the hole and skin were sealed with 
medical tissue glue (Aron Alpha A, Sankyo Inc., Tokyo, Japan). On the following day, 
110.7 μmol/kg of LVFX or LVFX-D6 (equivalent to 40 mg/kg LVFX), or 125.3 μmol/kg of 
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NFLX or NFLX-D6 (equivalent to 40 mg/kg NFLX) were injected via jugular vein. The mice 
were sacrificed by decapitation at fixed time intervals, and the infected right tibiae were 
dissected. Soft tissues were removed from the tibiae, and the tibiae were pulverized in 1 ml of 
saline. The suspensions were serially diluted in saline, and 0.025-ml aliquots of each dilution 
were plated onto Heart Infusion agar plates (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan). The 
plates were incubated overnight at 37°C, and the colonies were counted. 
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Results 
Synthesis and antibiotic activity of L-Asp hexapeptide-conjugated quinolones 
LVFX was conjugated with L-Asp hexapeptide via a glycolyl ester, and NFLX was 
conjugated via a glycolyl amide and subsequent succinate ester (Fig. 1). The synthetic yields of 
LVFX-D6 and NFLX-D6 from starting materials were 18.3 and 10.3%, respectively. The content 
of impurities such as LVFX in LVFX-D6 and NFLX or NFLX-ga in NFLX-D6 was 
approximately 0.5% for each preparation, as determined by HPLC analysis. The minimum 
inhibitory concentrations (MICs) of LVFX, LVFX-D6, NFLX, NFLX-ga, and NFLX-D6 with 
respect to S. aureus were determined by the serial dilution method (Table I). The conjugation of 
L-Asp hexapeptide significantly decreased the antibiotic activity of LVFX and NFLX; the 
activities of the non-conjugated forms were approximately 100-fold those of the conjugated 
forms. The MIC of NFLX-ga, which was expected to be generated through the biological 
hydrolysis of NFLX-D6, was 50% of the MIC of NFLX. 
 
Binding affinity of L-Asp hexapeptide-conjugated quinolones to hydroxyapatite 
At concentrations of 10 nmol/ml and lower, the amounts of LVFX-D6 and NFLX-D6 
that bound to hydroxyapatite were 10-fold the amounts of bound LVFX and NFLX, respectively 
(Fig. 2). However, the difference between the amounts of hydroxyapatite-bound LVFX and 
LVFX-D6 was less at 30 nmol/ml (2.0 nmol of LVFX versus 3.4 nmol of LVFX-D6 per 100 μg of 
hydroxyapatite). Appreciable quantities of NFLX and NFLX-ga did not bind to hydroxyapatite 
until their concentrations reached 30 μM. 
 
Pharmacokinetics and tissue distribution of L-Asp hexapeptide-conjugated quinolones 
After a single intravenous injection of LVFX, LVFX-D6, NFLX, or NFLX-D6, the 
concentrations of the compounds in bone and bone marrow were determined (Fig. 3). The 
amount of LVFX-D6 in bone was approximately 100-fold that of LVFX at 2 h after injection, and 
LVFX-D6 was retained in bone at a concentration 100-fold that of LVFX after 7 days. 
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Furthermore, the hydrolysis of LVFX-D6 maintained LVFX in the bone marrow for at least 7 
days, whereas in the group receiving LVFX, LVFX could not be detected in the bone marrow 
after 1 day. Similarly, the level of NFLX-D6 in bone was approximately 100-fold that of NFLX 
at 3 days after injection, and substantial amounts of NFLX-D6 were retained in bone for at least 7 
days. NFLX was undetectable by day 7. Neither NFLX nor NFLX-ga was detectable in bone 
marrow after an injection of NFLX or NFLX-D6, respectively. 
The plasma-concentration time courses of LVFX, LVFX-D6, NFLX, and NFLX-D6 after 
a single intravenous injection revealed biphasic behavior of these compounds (Fig. 4). The 
plasma concentrations of the conjugated quinolones were 2- to 3-fold those of the 
non-conjugated quinolones initially after injection, whereas the half-life in the plasma was 
similar between the conjugated and non-conjugated quinolones during the elimination phase. The 
plasma concentrations of LVFX-D6 and NFLX-D6 were higher than those of LVFX and NFLX, 
respectively, immediately after injection, but they rapidly decreased, falling to levels similar to 
those of LVFX and NFLX by 30 min. After an injection of LVFX-D6, LVFX, which might have 
been generated from LVFX-D6, appeared in the plasma; its concentration slowly decreased, and 
LVFX was not detectable after 90 min. In contrast, NFLX and NFLX-ga were not detected in the 
plasma until 6 h after an injection of NFLX-D6. 
At 2 h after a single intravenous injection, the apparent plasma-to-tissue concentration 
ratios (Kp,app) of LVFX, LVFX-D6, NFLX, and NFLX-D6 were determined (Fig. 5). In most of 
the soft tissues examined, except lung and kidney tissues, LVFX-D6 exhibited a restricted tissue 
distribution relative to LVFX after the injection of each, and LVFX was not detected in any of 
the soft tissues after an LVFX-D6 injection. NFLX-D6 also exhibited more limited tissue 
distribution, except in kidney tissue, than NFLX after their respective injections, and neither 
NFLX nor NFLX-ga was detected in the soft tissues after NFLX-D6 injection. 
 
Antibiotic effectiveness of L-Asp hexapeptide-conjugated quinolones in a mouse model of 
osteomyelitis 
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The antibiotic effectiveness of LVFX, LVFX-D6, NFLX, and NFLX-D6 was evaluated by 
counting the S. aureus colonies remaining in inoculated tibiae after a single intravenous injection 
of each compound (Fig. 6). In untreated control mice, the cfu of S. aureus reached a plateau at 2 
days after inoculation. With the injection of either LVFX or LVFX-D6 on the day following S. 
aureus inoculation, a slight reduction in cfu was observed. However, the antibiotic effectiveness 
of LVFX was temporary; after 6 days, the cfu recovered to levels similar to those in untreated 
control mice. A prolonged antibiotic effect was observed in mice treated with LVFX-D6, which 
suppressed the growth of S. aureus for at least 6 days. Conversely, neither NFLX nor NFLX-D6 
displayed any antibiotic efficacy in the osteomyelitis mouse model (data not shown). 
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Discussion 
In this study we examined the pharmacokinetics and pharmacodynamics of quinolones 
conjugated with L-Asp hexapeptide as a bone-targeting carrier. We demonstrated that the 
conjugated quinolones localize to bone, where they were retained for longer times compared 
with the non-conjugated quinolones and exhibit prolonged antibiotic effects in mice with 
osteomyelitis.  
Quinolones act by inhibiting bacterial topoisomerase II, which is responsible for the 
replication of double-stranded DNA, and they therefore must cross the bacterial membrane to be 
effective (26, 27). Specifically, the 3-carboxylate group, a basic structure of quinolones, mediates 
binding to topoisomerase II (28). As this structure would be obstructed by the direct conjugation 
of LVFX to the L-Asp hexapeptide moiety, we created a glycolyl ester of LVFX in order to 
introduce a biologically hydrolysable spacer between LVFX and the L-Asp hexapeptide. To 
avoid modification of the 3-carboxylate moiety of NFLX, we conjugated L-Asp hexapeptide to 
the secondary amine of the piperazine ring. However, NFLX-D6 had substantially reduced 
antibiotic activity compared with NFLX and NFLX-ga. It is well known that the accumulation of 
quinolones in Gram-positive bacteria correlates with the hydrophobicity of the molecule, which 
implies that quinolones cross bacterial membranes by simple diffusion (29-31). The partition 
coefficients of the conjugated quinolones in n-octanol/aqueous buffer and chloroform/aqueous 
buffer were approximately 100-fold less than those of the non-conjugated quinolones (data not 
shown). Thus, the conjugation of hydrophilic amino acids, specifically L-Asp hexapeptide, 
reduced the hydrophobicity of the quinolones, and the conjugated quinolones could not cross the 
bacterial membrane until the L-Asp hexapeptide was removed by ester hydrolysis.  
Compared with the non-conjugated quinolones, the conjugated quinolones exhibited 
increased binding affinity to hydroxyapatite in vitro and consistently higher bone concentrations 
in vivo. Furthermore, the hydrolyzed product of LVFX-D6, LVFX, was detected in the plasma 
and bone marrow after the injection of LVFX-D6. These findings strongly support using 
LVFX-D6 as an osteomyelitis treatment. Indeed, LVFX-D6 suppressed the growth of S. aureus 
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for at least 6 days in a mouse model of osteomyelitis, thus exhibiting prolonged antibiotic 
activity. However, the antibiotic effect of LVFX-D6 was not entirely bactericidal, presumably 
because the concentration of LVFX generated from hydrolyzed LVFX-D6 was insufficient to kill 
S. aureus in bone. NFLX-D6 showed no efficacy in this model of osteomyelitis, nevertheless 
NFLX-D6 was highly accumulated in bone at approximately 5-fold the concentration of 
LVFX-D6. The 3-carboxylate and 4-carbonyl groups in quinolone are known to be responsible 
for potential chelating property with divalent metals such as calcium existing in bone, and these 
groups remain intact in NFLX-D6, but not in LVFX-D6 (32). It is also known that the extension 
of the number of acidic amino acid increases the bone accumulating property of acidic 
oligopeptide in vivo (21). Thus, it was hypothesized that the intact 3-carboxylate and 4-carbonyl 
groups in NFLX-D6 further augmented the affinity of L-Asp hexapeptide to bone. Although the 
hydrolyzed product of NFLX-D6, NFLX-ga, was not detected in bone marrow after an injection 
of NFLX-D6, this might be attributable to a lower detection limit of NFLX-ga compared with 
LVFX. Given the similar decline in the bone concentrations of NFLX-D6 and LVFX-D6, 
NFLX-ga might be continuously released. Taken together, we expect that the limited 
effectiveness of NFLX-D6 in this model of osteomyelitis may be due to both NFLX and 
NFLX-ga have lower antibiotic activity toward S. aureus compared with LVFX. The bactericidal 
effect of quinolones is concentration dependent, with a higher concentration of quinolone 
producing a more complete killing effect (33, 34). Thus, a high hydrolytic rate of the conjugated 
quinolones appears to be important for maximal antibiotic effect.  
Quinolones extensively penetrate tissues and consequently may cause adverse effects in 
the cardiovascular system, central nervous system, skin, liver, musculoskeletal system, and 
kidneys (35-37). The conjugated quinolones showed reduced tissue distribution, probably owing 
to their increased hydrophilicity. Both LVFX-D6 and NFLX-D6 were distributed to the kidneys at 
concentrations 2- to 3-fold those of LVFX and NFLX, respectively, at 2 h after injection. 
However, the levels of the conjugated quinolones returned to those of the non-conjugated 
quinolones by 4 h (Fig 7). Quinolones are excreted entirely via the kidneys, and the increased 
14 
hydrophilicity of the conjugated quinolones may facilitate their accumulation in the kidneys (38, 
39). This renal accumulation may also be partly due to the higher plasma concentration, which is 
a result of the lower tissue distribution, at an early time after injection. In addition, the acidic 
oligopeptide was eliminated by renal excretion, and the plasma half-life decreased with 
increasing number of acidic amino acid residues (21). Thus, the L-Asp hexapeptide altered the 
renal distribution of quinolones, although the influence of L-Asp hexapeptide on the renal 
pharmacokinetics, including glomerular filtration, tubular secretion, and tubular re-absorption, 
remains to be solved. The accumulation of conjugated quinolones could increase the risk of 
adverse events such as azotemia, nephropathy, and interstitial nephritis; meanwhile, the risk of 
adverse events involving other tissues may be decreased. 
When conjugated to an acidic oligopeptide, the common quinolones LVFX and NFLX 
are model drugs that highlight the clinical feasibility of using a bone-targeting strategy in the 
treatment of osteomyelitis. To increase the therapeutic effectiveness of this treatment strategy, 
other compounds with greater initial antibiotic activity could be used, as peptide conjugation is 
applicable to molecules of all sizes, including enzymes (22, 40-42). Further modifications should 
also be considered to ensure biological hydrolysis of acidic oligopeptide-conjugated compounds, 
although the mechanism of hydrolysis remains to be resolved. 
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Figure legends 
Fig. 1. Molecular structures of LVFX, glycolyl ester of LVFX (LVFX-ga), LVFX-D6, NFLX, 
glycolyl-NFLX (NFLX-ga), glycolyl-NFLX hemisuccinate (NFLX-ga-suc), and NFLX-D6. 
 
Fig. 2. Concentration-dependent binding curves of L-Asp hexapeptide-conjugated and 
non-conjugated quinolones to hydroxyapatite. Final concentrations of 0.1 to 30 μM of each 
compound, A) LVFX (○) and LVFX-D6 (●), and B) NFLX (○), NFLX-ga (△), and NFLX-D6 
(●), were incubated with 100 μg of hydroxyapatite at 37°C for 1 h. The unbound quinolone was 
separated from the bound quinolone by centrifugation and the concentration of unbound 
quinolone in the supernatant was measured. The amount of bound quinolone was calculated by 
subtracting the unbound from the total. L-Asp hexapeptide conjugation significantly increased 
the binding affinity of quinolones to hydroxyapatite. Each point with a bar represents the mean ± 
SE of 3-6 experiments. 
 
Fig. 3. Time course of bone and bone marrow concentrations of L-Asp hexapeptide-conjugated 
and non-conjugated quinolones. A dosage of A) 27.7 μmol/kg of LVFX (○) or LVFX-D6 (●), or 
B) 31.3 μmol/kg of NFLX (○) or NFLX-D6 (●) was intravenously injected into mice, and the 
concentrations in the tibia were determined at the indicated time points. The L-Asp 
hexapeptide-conjugated quinolones were concentrated and retained in bone at approximately 
100-fold the concentrations of non-conjugated quinolones for at least 7 days after injection. C) In 
bone marrow, LVFX was detected at 2 h after an injection of LVFX (○) or LVFX-D6 (●). The 
LVFX concentration declined to an undetectable level within 1 day after LVFX injection, 
whereas LVFX continued to be generated for at least 7 days after LVFX-D6 injection. Neither 
NFLX nor NFLX-ga was detected in bone marrow after injection of either NFLX or NFLX-D6, 
respectively. Each point with a bar represents the mean ± SE of four mice. 
 
Fig. 4. Time course of plasma concentrations of L-Asp hexapeptide-conjugated and 
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non-conjugated quinolones. A dosage of A) 27.7 μmol/kg of LVFX (○) or LVFX-D6 (●), or B) 
31.3 μmol/kg of NFLX (○) or NFLX-D6 (●) was intravenously injected into mice, and the 
concentrations in plasma were determined at the indicated time points. All the compounds were 
eliminated from the plasma in a biphasic manner. The plasma concentrations of the conjugated 
quinolones were 2- to 3-fold those of the non-conjugated quinolones initially after injection. 
However, the half-life was similar between the conjugated and non-conjugated quinolones during 
the elimination phase. The hydrolyzed product LVFX (■), which was shown in A), was detected 
in the plasma after LVFX-D6 injection, and LVFX was eliminated slowly from the plasma. The 
predicted hydrolyzed products of NFLX-D6 (NFLX and NFLX-ga) were not detected in the 
plasma after NFLX-D6 injection. Each point with a bar represents the mean ± SE of four mice. 
 
Fig. 5. Tissue distribution of L-Asp hexapeptide-conjugated and non-conjugated quinolones. A 
dosage of A) 27.7 μmol/kg of LVFX (□) or LVFX-D6 (■), or B) 31.3 μmol/kg of NFLX (□) or 
NFLX-D6 (■) was intravenously injected into mice, and the concentration of each compound 
was determined in the indicated tissues at 2 h after injection. The amounts of the L-Asp 
hexapeptide-conjugated quinolones were less than the amounts of the non-conjugated quinolones 
in most tissues, with the exception of lung and kidney tissues. The predicted products of 
hydrolysis (LVFX, NFLX, and NFLX-ga) were not detected in any of the soft tissues examined. 
Each column with a bar represents the mean ± SE of four mice. Kp,app; apparent 
plasma-to-tissue concentration ratios. 
 
Fig. 6. Antibiotic effectiveness of LVFX and LVFX-D6 in a mouse model of osteomyelitis. One 
microliter containing 105 cfu of S. aureus was inoculated into the tibiae of mice. The following 
day, LVFX (○) or LVFX-D6 (●) at 110.7 μmol/kg was intravenously injected, and the quantity 
of surviving S. aureus colonies was determined at the indicated time points. The cfu in untreated 
control mice (△) reached a plateau 2 days post-inoculation, whereas both LVFX and LVFX-D6 
significantly suppressed the growth of S. aureus. The antibiotic efficacy of LVFX-D6 continued 
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for at least 6 days after injection, but the effectiveness of LVFX was temporary. Each point with 
a bar represents the mean ± SE of 8-12 mice. *, **; significantly different from untreated control 
mice at p < 0.05 and p < 0.01, respectively. †; significantly different from LVFX-treated mice at 
p < 0.01. 
 
Fig. 7. Time course of kidney concentrations of L-Asp hexapeptide-conjugated and 
non-conjugated quinolones. A dosage of A) 27.7 μmol/kg of LVFX (○) or LVFX-D6 (●), or B) 
31.3 μmol/kg of NFLX (○) or NFLX-D6 (●) was intravenously injected into mice, and the 
concentrations in kidney were determined at the indicated time points. The L-Asp 
hexapeptide-conjugated quinolones were concentrated in kidney at approximately two-fold the 
concentrations of non-conjugated quinolones at 2 h after injection. At 4 h, however, the kidney 
concentrations of the L-Asp hexapeptide-conjugated quinolones fell in the similar level as 
non-conjugated quinolones. Each point with a bar represents the mean ± SE of four mice. 
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Table I. In vitro antibiotic activities of L-Asp hexapeptide-conjugated and non-conjugated 
quinolones against Staphylococcus aureus. 






aMIC, minimum inhibitory concentration; the lowest concentration of a compound that inhibited 
visible growth of S. aureus after overnight incubation at 37°C in Mueller-Hinton broth. 
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